x

Posted 22 February, 2024

SYNLOGIC, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:SYBX in a 8-K filed on 22 February, 2024.


  As previously disclosed, Synlogic, Inc. (the "Company") and Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, agreed that Dr. Brennan's employment with the Company will terminate effective March 9, 2024 (the "Brennan Separation").  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of SYNLOGIC, INC.
Health Care/Life Sciences • Biotechnology
Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.
Market Cap
$16.8M
View Company Details
SYNLOGIC, INC. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Aoife Brennan, M.B., Ch.B. 

As previously disclosed, Synlogic, Inc. (the "Company") and Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, agreed that Dr. Brennan's employment with the Company will terminate effective March 9, 2024 (the "Brennan Separation"). In connection with the Brennan Separation, the Company entered into a separation agreement with Dr. Brennan on February 17, 2024, to be effective on February 25, 2024 (the "Brennan Separation Agreement"). Pursuant to the terms of the Brennan Separation Agreement, Dr. Brennan's employment with the Company will end on March 9, 2024 (the "Brennan Departure Date"). Dr. Brennan will assist the Company through the Brennan Departure Date in the transition of work in connection with her duties as President and Chief Executive Officer of the Company.

In consideration for, among other things, her compliance with certain restrictive covenants and a typical release of claims, Dr. Brennan shall receive a lump-sum payment equal to $628,305, which is equivalent to twelve months of her base salary. Additionally, Dr. Brennan will be eligible for consideration of 100% of her target 2024 bonus, pro-rated by the number of days employed in 2024, in the amount of $65,327. The determination of whether to award a bonus and the amount of bonus shall be in the sole discretion of the Company. Dr. Brennan is also entitled to continued health insurance coverage for up to twelve months following the Brennan Departure Date.

The foregoing description of the material terms of the Brennan Separation Agreement is qualified in its entirety by the full text of the Brennan Separation Agreement, a copy of which will be filed as an exhibit to the Company's annual report on Form 10-K for the year ending December 31, 2023.

Antoine Awad 

On February 17, 2024, the Company entered into a separation agreement with Antoine Awad, Chief Operating Officer, to be effective on February 25, 2024 (the "Awad Separation Agreement"), pursuant to which, Mr. Awad's employment with the Company will end on May 30, 2024 (the "Awad Departure Date"). Mr. Awad will assist the Company through the Awad Departure Date in the transition of work in connection with his duties as Chief Operating Officer of the Company.

In consideration for, among other things, his compliance with certain restrictive covenants and a typical release of claims, Mr. Awad shall receive a lump-sum payment equal to $218,856, which is equivalent to six months of his base salary. Additionally, Mr. Awad will be eligible for consideration of 100% of his target 2024 bonus, pro-rated by the number of days employed in 2024, in the amount of $87,302. The determination of whether to award a bonus and the amount of bonus shall be in the sole discretion of the Company. Mr. Awad is also entitled to continued health insurance coverage for up to six months following the Awad Departure Date.

The foregoing description of the material terms of the Awad Separation Agreement is qualified in its entirety by the full text of the Awad Separation Agreement, a copy of which will be filed as an exhibit to the Company's annual report on Form 10-K for the year ending December 31, 2023.